---
layout: default
title: Acer Negundo Pollen Acer Pseudoplatanus Pollen Act
parent: 僅模型預測 (L5)
nav_order: 66
evidence_level: L5
indication_count: 0
---

# Acer Negundo Pollen Acer Pseudoplatanus Pollen Act
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Combination: Evaluation Halted — Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This candidate consists of an 18-component mixture including tree pollens, classical homeopathic botanicals (Pulsatilla vulgaris, Strychnos nux-vomica seed, Atropa belladonna), activated charcoal, arsenic trioxide, and sodium chloride — a profile consistent with a homeopathic allergy or respiratory product. The TxGNN pipeline returned **no predicted indications** for this candidate, and the drug holds **no US marketing authorization**. Without predicted indications, mechanism-of-action data, or any regulatory reference, a meaningful repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no regulatory records found) |
| Predicted New Indication | None returned by TxGNN |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why This Prediction Cannot Be Assessed

The Evidence Pack contains no predicted indications from TxGNN, which means the model either did not recognize any component as a mappable DrugBank entity, or the combination as a whole falls outside the knowledge graph's coverage.

Several features of this formulation make standard repurposing evaluation difficult:

1. **Homeopathic composition**: The majority of ingredients (Pulsatilla vulgaris, Lycopodium clavatum spore, Euphrasia officinalis leaf, Atropa belladonna, Strychnos nux-vomica seed) are classical homeopathic substances used at high dilutions. Their pharmacological mechanism at the molecular level is not established in the conventional biomedical literature, and DrugBank does not maintain structured MOA records for most of them.

2. **Multi-component complexity**: With 18 named ingredients, it is not possible to identify which component, if any, the TxGNN model should evaluate. The pipeline appears to have treated the entire string as a single entity, which returned no match.

3. **Arsenic trioxide anomaly**: One component — arsenic trioxide — does have a well-characterized mechanism (PML-RARα degradation in acute promyelocytic leukemia) and an FDA-approved indication. However, in this formulation it is presumably present at homeopathic dilution, making direct extrapolation from its conventional pharmacology inappropriate.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on arsenic trioxide**: If this compound is intended for use at pharmacologically active (non-homeopathic) concentrations, arsenic trioxide carries an FDA Boxed Warning for QTc prolongation, APL differentiation syndrome, and electrocardiographic monitoring requirements. This should be clarified before any further development work.

---

## US Market Information

No US marketing authorizations on record for this combination.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN returned no predicted indications for this candidate, and the absence of DrugBank mapping, MOA data, and any regulatory history makes it impossible to conduct a meaningful repurposing evaluation. The formulation's homeopathic nature places it outside the standard biomedical knowledge graph used by TxGNN.

**To proceed, the following is needed:**

- **Clarify product identity**: Confirm whether this is a registered homeopathic product or a conventional pharmaceutical. If homeopathic, standard repurposing pipelines are not applicable.
- **Decompose the combination**: If repurposing evaluation is desired, each active component (particularly arsenic trioxide) should be submitted to TxGNN individually with its own DrugBank ID.
- **Establish original indication**: Identify the intended therapeutic use to provide context for any downstream analysis.
- **Obtain MOA data**: Query DrugBank for each individual component to build a mechanistic profile.
- **Regulatory clarification for arsenic trioxide**: If arsenic trioxide is present at pharmacologically active concentrations, obtain the package insert and safety data before any clinical development planning.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

